1. Home
  2. RIGL vs BBW Comparison

RIGL vs BBW Comparison

Compare RIGL & BBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • BBW
  • Stock Information
  • Founded
  • RIGL 1996
  • BBW 1997
  • Country
  • RIGL United States
  • BBW United States
  • Employees
  • RIGL N/A
  • BBW N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • BBW Recreational Games/Products/Toys
  • Sector
  • RIGL Health Care
  • BBW Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • BBW Nasdaq
  • Market Cap
  • RIGL 486.4M
  • BBW 527.5M
  • IPO Year
  • RIGL 2000
  • BBW 2004
  • Fundamental
  • Price
  • RIGL $21.81
  • BBW $40.04
  • Analyst Decision
  • RIGL Buy
  • BBW Strong Buy
  • Analyst Count
  • RIGL 5
  • BBW 3
  • Target Price
  • RIGL $34.80
  • BBW $54.33
  • AVG Volume (30 Days)
  • RIGL 347.9K
  • BBW 314.4K
  • Earning Date
  • RIGL 03-04-2025
  • BBW 03-13-2025
  • Dividend Yield
  • RIGL N/A
  • BBW 2.01%
  • EPS Growth
  • RIGL N/A
  • BBW 8.16
  • EPS
  • RIGL 0.22
  • BBW 3.79
  • Revenue
  • RIGL $157,374,000.00
  • BBW $495,235,000.00
  • Revenue This Year
  • RIGL $51.34
  • BBW $2.53
  • Revenue Next Year
  • RIGL $15.75
  • BBW $2.59
  • P/E Ratio
  • RIGL $98.50
  • BBW $10.57
  • Revenue Growth
  • RIGL 21.65
  • BBW 2.76
  • 52 Week Low
  • RIGL $7.48
  • BBW $21.42
  • 52 Week High
  • RIGL $29.82
  • BBW $48.23
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 64.53
  • BBW 43.60
  • Support Level
  • RIGL $17.28
  • BBW $38.26
  • Resistance Level
  • RIGL $18.25
  • BBW $42.12
  • Average True Range (ATR)
  • RIGL 1.37
  • BBW 1.75
  • MACD
  • RIGL 0.65
  • BBW -0.87
  • Stochastic Oscillator
  • RIGL 99.68
  • BBW 19.82

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

Share on Social Networks: